Spero Therapeutics Announces 3Q17 Operating Results and Pipeline Update
December 14, 2017 16:15 ET
|
Spero Therapeutics, Inc.
Raised approximately $83.6 million in gross proceeds from Initial Public OfferingAdvanced pipeline with initiation of SPR994 Phase 1 trial in October 2017 and SPR741 Phase 1b trial in November 2017 ...
Spero Therapeutics Announces Underwriters’ Option Exercise
November 13, 2017 07:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Closing of Initial Public Offering
November 06, 2017 16:01 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Announces Pricing of Initial Public Offering
November 01, 2017 18:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Launches Initial Public Offering
October 23, 2017 07:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
October 20, 2017 08:00 ET
|
Spero Therapeutics, Inc.
Clinical study to evaluate potential first ever orally administered carbapenem being developed for multi-drug resistant (MDR) Gram-negative infectionsInitiation of pivotal Phase 3 clinical trial in...
Spero Therapeutics Licenses Exclusive Rights to SPR994, a Novel Oral Carbapenem Being Studied for Use in Adults
October 10, 2017 08:00 ET
|
Spero Therapeutics
-Spero and Meiji Seika Pharma Co., LTD. announce an exclusive license partnership for SPR994 -FDA grants SPR994 Qualified Infectious Disease Product (QIDP) status for complicated urinary tract...
Spero Therapeutics Files Registration Statement for Proposed Initial Public Offering
October 06, 2017 16:26 ET
|
Spero Therapeutics
CAMBRIDGE, Mass., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (“Spero”), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing...
Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
October 03, 2017 08:00 ET
|
Spero Therapeutics
CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel...
Spero Announces Appointment of Frank Thomas to its Board of Directors and Promotions within Leadership Team
September 06, 2017 08:00 ET
|
Spero Therapeutics
Cristina Larkin promoted to Chief Operating Officer Timothy Keutzer Promoted to Senior Vice President, Development CAMBRIDGE, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc., a...